Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters

被引:36
作者
Song, YJ
Qu, CF
Rizvi, SMA
Li, Y
Robertson, G
Raja, C
Morgenstern, A
Apostolidis, C
Perkins, AC
Allen, BJ
机构
[1] St George Hosp, Canc Care Ctr, Ctr Expt Radiat Oncol, Kogarah, NSW 2217, Australia
[2] Univ New S Wales, Sydney, NSW 2052, Australia
[3] St George Hosp, Dept Genecol, Kogarah, NSW 2217, Australia
[4] Commiss European Communities, Joint Res Ctr, Inst Transuranium Elements, D-76125 Karlsruhe, Germany
[5] Queens Med Ctr, Sch Med, Dept Med Phys, Nottingham NG7 2UH, England
关键词
radioimmunotherapy; Bismuth-213; ovarian cancer cell line; MUC1; uPA; HER2;
D O I
10.1016/j.canlet.2005.03.060
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The vectors PAI2, C595 and Herceptin target the membrane-bound uPA, MUCl and HER2 antigens expressed by cancer cells, respectively. The expression of these receptors was tested in the ovarian cancer cell line OVCAR-3; MUC-1 was strongly expressed (3+), uPA moderately expressed (2+), but HER2 was negative (-). The alpha-emitting radionuclide Bismuth-213 was chelated with these targeting vectors to form alpha conjugates (ACs), the cytotoxicity of which were tested with OVCAR-3 cells. The PAI2 and C595 ACs are highly cytotoxic to the ovarian monolayer cancer cells and cell clusters in a concentration-dependent fashion and cause morphological changes of treated cancer cells, inducing apoptosis. These ACs are potential candidates for the control of ovarian cancer at the minimum residual disease (MRD) stage. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:176 / 183
页数:8
相关论文
共 26 条
[1]  
Allen B J, 1999, Australas Radiol, V43, P480, DOI 10.1046/j.1440-1673.1999.00717.x
[2]  
Allen BJ, 1999, NUCL MED COMMUN, V20, P205
[3]   The plasminogen activation system in tumor growth, invasion, and metastasis [J].
Andreasen, PA ;
Egelund, R ;
Petersen, HH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) :25-40
[4]  
Bolis G, 1996, CANCER, V77, P128, DOI 10.1002/(SICI)1097-0142(19960101)77:1<128::AID-CNCR21>3.3.CO
[5]  
2-D
[6]   High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer [J].
Borgfeldt, C ;
Bendahl, PO ;
Gustavsson, B ;
Långström, E ;
Fernö, W ;
Willén, R ;
Grenman, S ;
Casslén, B .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (04) :658-665
[7]   MECHANISMS UNDERLYING ABERRANT GLYCOSYLATION OF MUC1 MUCIN IN BREAST-CANCER CELLS [J].
BROCKHAUSEN, I ;
YANG, JM ;
BURCHELL, J ;
WHITEHOUSE, C ;
TAYLORPAPADIMITRIOU, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 233 (02) :607-617
[8]   HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].
CARTER, P ;
PRESTA, L ;
GORMAN, CM ;
RIDGWAY, JBB ;
HENNER, D ;
WONG, WLT ;
ROWLAND, AM ;
KOTTS, C ;
CARVER, ME ;
SHEPARD, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289
[9]   Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer [J].
Croce, MV ;
Isla-Larrain, MT ;
Rua, CE ;
Rabassa, ME ;
Gendler, SJ ;
Segal-Eiras, A .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2003, 51 (06) :781-788
[10]   Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas [J].
Feng, H ;
Ghazizadeh, M ;
Konishi, H ;
Araki, T .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (12) :525-529